Skip to main content

Table 2 Clinical efficacy of NGX-4010 in all patients with PHN

From: Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia

NPRS Scores NGX-4010
(n = 102)
Control
(n = 53)
P-value
Baseline, LS mean (SE) 5.4 (0.16) 5.3 (0.22)  
   95% CI 5.12, 5.73 4.87, 5.72  
Change, mean (SE)    
   Baseline to weeks 2 to 8 -1.8 (0.20) -1.6 (0.27) 0.462
   95% CI -2.23, -1.45 -2.13, -1.05  
   Baseline to weeks 2 to 12 -1.8 (0.20) -1.7 (0.28) 0.750
   95% CI -2.25, -1.45 -2.29, -1.18  
Percent Change, mean (SE)    
   Baseline to weeks 2 to 8 -36.5 (3.68) -29.9 (5.10) 0.296
   95% CI -43.72, -29.19 -39.94, -19.78  
   Baseline to weeks 2 to 12 -36.6 (3.75) -32.3 (5.21) 0.509
   95% CI -44.02, -29.19 -42.63, -22.05  
Patients with ≥ 30% reduction, %    
   Baseline to weeks 2 to 8 49 45 0.574
   Baseline to weeks 2 to 12 49 49 0.956
Patients with ≥ 50% reduction, %    
   Baseline to weeks 2 to 8 36 36 0.930
   Baseline to weeks 2 to 12 39 36 0.628
PGIC    
   Improved (very much, much)    
   Week 4, n 100 49  
N (%) 40 (40) 19 (39) 1.0000
   Week 8, n 91 43  
N (%) 43 (47) 14 (33) 0.1351
   Week 12, n 95 50  
N (%) 41 (43) 15 (30) 0.1518